Company Overview
Pharvaris N.V. operates as a late-stage biopharmaceutical company dedicated to the development and commercialization of therapies addressing rare diseases with unmet medical needs, specifically focusing on conditions mediated by bradykinin such as angioedema. The company functions within the Healthcare sector and the Biotechnology industry, an environment characterized by high R&D expenditures and regulatory scrutiny regarding novel therapeutic candidates like deucrictibant, a small molecule bradykinin B2-receptor antagonist. Currently, the organization employs 118 individuals to advance its clinical pipeline and operational infrastructure. With a market capitalization of $1.70B, the company holds a significant valuation position in the biotech space, though the absence of reported revenue in the trailing twelve months indicates that its current market value is derived primarily from its intellectual property, clinical data, and future commercial potential rather than current sales performance.
Financial Health
The company reported a net income of $-163,719,488 and an EBITDA of $-167,259,872 over the trailing twelve months, while revenue figures are not disclosed. The substantial gap between the reported net income and EBITDA highlights a significant tax benefit or specific non-operating income items that offset the underlying operational losses, yet the overall financial position remains deeply negative, reflecting the capital-intensive nature of late-stage biotechnology development. Free cash flow stands at $-76,153,248, indicating that the company is burning cash to fund its research and development activities, which limits immediate financial flexibility and necessitates reliance on existing cash reserves or external capital raises. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure typical for biotechnology firms in pre-revenue or early commercial stages where costs vastly outweigh recognized revenue. Despite the negative earnings, the company holds $329.29M in cash against total debt of $578,657, resulting in a debt-to-equity ratio of 0.18. This balance sheet structure suggests a conservative approach to leverage, as the company carries minimal debt relative to its equity and cash position. Liquidity is robust, evidenced by a current ratio of 12.86, which implies the company possesses more than twelve times the current assets necessary to cover its short-term liabilities. Return on Equity is -53.8% and Return on Assets is -32.1%, metrics that reveal management is currently deploying capital in a manner that generates negative returns, a common but high-risk characteristic of companies attempting to prove clinical viability before achieving profitability.
Valuation Assessment
The trailing twelve-month P/E ratio is not applicable due to negative earnings, while the forward P/E is listed at -8.17, a metric that lacks traditional interpretability when earnings are negative but signals that the market is pricing in significant future earnings growth expectations. The price-to-book ratio is 4.69, indicating that the market values the company at a premium of 4.69 times its net asset book value, a valuation multiple often seen in biotech firms where intangible assets and pipeline potential exceed the value of physical assets. The price-to-sales ratio is not applicable given the lack of revenue data, and the EV/EBITDA stands at -8.13, suggesting that valuation is currently disconnected from earnings power and driven by cash reserves and clinical milestones. Regarding price action, the 52-week high was $29.80 and the 52-week low was $11.51; without a specific current price provided in the available facts, the exact percentage deviation cannot be calculated, but the range demonstrates substantial volatility within the year. The stock exhibits a beta of -2.71, a highly unusual negative coefficient that implies the stock price tends to move in the opposite direction of the broader market, suggesting a unique sensitivity to sector-specific factors or market sentiment that inversely correlates with general market movements.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, precluding a direct comparison of growth rates between the two metrics due to the absence of positive revenue baselines. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company retains all available cash flow to reinvest into its clinical trials and commercialization efforts rather than distributing income to shareholders. The absence of a dividend program is consistent with the growth-stage profile of a biotechnology company, where capital allocation prioritizes funding research and development to achieve regulatory approval and market entry. Consequently, the overall growth and income profile is defined entirely by the potential for future revenue realization and capital appreciation, as the current financial structure supports no income generation but focuses resources on transforming the company from a research entity into a revenue-producing pharmaceutical firm.